Introduction
============

Pancreatic cancer is expected to be the second most lethal malignancy in the USA by 2020, and the 5-year survival rate for patients diagnosed with locally advanced or metastatic pancreatic cancer remains \<3% ([@b1-mmr-16-04-4784],[@b2-mmr-16-04-4784]). The efficacy of traditional chemoradiotherapies for pancreatic cancer remains limited ([@b3-mmr-16-04-4784]--[@b5-mmr-16-04-4784]). However, no effective targeted therapies or screening tests for pancreatic cancer are recently available, and no clinically comfirmed biomarkers are available for identifying subsets of patients who might benefit from chemoradiotherapies or targeted theprapies ([@b6-mmr-16-04-4784]--[@b9-mmr-16-04-4784]). Different from frequent liver and peritoneum metastases, the bone metastasis rate of pancreatic cancers is quite low but reaches higher of about 7.3% with the improvement of the diagnosis and treatment level ([@b10-mmr-16-04-4784],[@b11-mmr-16-04-4784]). For pancreatic cancer patients, especially those in advanced or metastatic disease stages, individualized drug screening is urgently needed for the clinical treatment.

The lack of an appropriate *in vivo* model for preclinical studies has limited the mechanistic study of tumor resistance to anti-VEGF therapy. Patient-derived xenografts (PDXs), so-called Avatar models ([@b12-mmr-16-04-4784]), have been increasingly widely used in various types of cancers for translational research in recent years, with the greatest advantage of its ability to better predict clinical tumor response ([@b13-mmr-16-04-4784]). Accumulating evidence indicates that PDX is an reliable cancer research tool for drug screening and personalized medicine applications ([@b14-mmr-16-04-4784]).

It is known that somatic genomic alterations alter the function of genes or pathways, thus resulting in tumorigenesis, metastasis, and resistance to therapies ([@b15-mmr-16-04-4784],[@b16-mmr-16-04-4784]). Therefore, precise molecular profiles of tumors will help to predict drug responses ([@b17-mmr-16-04-4784]). Understanding the genomic landscape of CRC can contribute to drug screening ([@b8-mmr-16-04-4784],[@b18-mmr-16-04-4784]--[@b20-mmr-16-04-4784]). Large-scale sequencing projects has economically led to the rapid development and clinical popularization of next-generation sequencing (NGS) technologies ([@b21-mmr-16-04-4784]). NGS can be a powerful tool to understand the genomic landscape of patients and mechanism of drug response, which thus might provide a more broad vision for clinically potential drug screening ([@b22-mmr-16-04-4784]--[@b24-mmr-16-04-4784]). Therefore, NGS technologies are being used by pharmaceutical companies throughout the drug discovery process ([@b21-mmr-16-04-4784]).

In our previous studies, we established a series of PDX models of different tumor types and accumulated substantial experiences of drug evaluation, screening and mechanism exploration ([@b25-mmr-16-04-4784],[@b26-mmr-16-04-4784]). While in the present study, we established a PDX model by pancreatic cancer bone metastasis tumor tissues for evaluation of potential drugs for pancreatic cancer patient. In our study, in order to select the optimal therapy for the patient, the NGS technology was used for investigating of tumor molecular characteristics and searching for potential drugs, which were finally evaluated in the corresponding PDX model. The aim of our study is to demonstrate the feasibility of the novel NGS-PDX based drug screening pattern which has a great potential to improve the cancer individualized treatment.

Materials and methods
=====================

### Reagents and drugs

AZD6244 (cat. no. S1008) and Capecitabine (cat. no. S1156) were purchased from Selleck Chemicals (Shanghai, China). The antibodies against ki-67, CK19, CK7, PCNA, Caspase-3, ERK, p-ERK, and β-actin were purchased from Abcam (Cambridge, UK).

### Patient and tumor tissues

Pancreatic cancer bone metastasis (diagnosed as adenocarcinoma) tissues were obtained at surgery from a 67-year-old female patient. A single bone metastasis was imageologically found at the right pedicle of L2 vertebral arch, which means a high risk of fracture and paraplegia. In addition, the patient urged for operation treatment. The study was done in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization and Good Clinical Practice guidelines. The Institutional Ethical Committee approved the current study.

### Establishment of PDX model

BALB/c nude mice (3-to-4-week-old, female) were purchased from Shanghai Slaccas Laboratory Animal and housed in SPF laboratory animal rooms at laboratory animal center of Zhejiang University. Mice were acclimated to new environments for at least 3 days before use. Surgical tumor tissues were cut into pieces of 3 to 4 mm and transplanted within 30 min s.c. to mice. Additional tissues were snap-frozen and stored at −80°C until use. Animals were monitored periodically for their weight with an electronic balance and tumor growth with a Vernier caliper twice every week. The tumor volume was calculated as formula V=LD × (SD)^2^/2, where V represents the tumor volume, LD and SD are the longest and the shortest tumor diameter, respectively. Tumors were then harvested, minced and re-implanted as described above for passaging. At each generation, tumors were harvested and stored in liquid nitrogen for further use. The usage of experimental animals was according to the Principles of Laboratory Animal Care (NIH \#85-23, 1985 version). All animal studies were according to the Institutional Animal Care and Use Committee of Zhejiang University, and the approval ID was SYXK (ZHE) 2005--0072.

### Multiple gene mutation analysis by next generation sequencing

The sequencing including 416 gene exons was conducted by Geneseeq Technology Inc. (Nanjing, China). ctDNA was extracted from patient\'s tumor. The purified ctDNA is quantified by a Picogreen fluorescence assay using the provided lambda DNA standards (Invitrogen Life Technologies, Carlsbad, CA, USA). Then, library construction with the KAPA Hyper DNA Library Prep Kit, containing mixes for end repair, dA addition and ligation, were performed in 96-well plates (Eppendorf). Dual-indexed sequencing libraries are PCR amplified for 4--7 cycles. The 5′-biotinylated probe solution is provided as capture probes, the baits target 416 cancer-related genes. 1 µg of each ctDNA-fragment sequencing library is mixed with 5 µg of human Cot-1 DNA, 5 µg of salmon sperm DNA, and 1 unit adaptor-specific blocker DNA in hybridization buffer, heated for 10 min at 95°C, and held for 5 min at 65°C in the thermocycler. Within 5 min, the capture probes are added to the mixture, and the solution hybridization is performed for 16--18 h at 65°C. After hybridization is complete, the captured targets are selected by pulling down the biotinylated probe/target hybrids using streptavidin-coated magnetic beads, and off-target library is removed by washing with wash buffer. The PCR master mix is added to directly amplify (6--8 cycles) the captured library from the washed beads. After amplification, the samples are purified by AMPure XP beads, quantified by qPCR (Kapa Biosystems, Inc., Wilmington, MA, USA) and sized on bioanalyzer 2100 (Agilent Technologies, Inc., Santa Clara, CA, USA). Libraries are normalized to 2.5 nM and pooled. Deep Sequencing is performed on Illumina HiSeq 4000 using PE75 V1 kit. Cluster generation and sequencing is performed according to manufacturer\'s protocol. Base calling was performed using bcl2fastq v2.16.0.10 (Illumina, Inc., San Diego, CA, USA) to generate sequence reads in FASTQ format (Illumina 1.8+ encoding). Quality control (QC) was applied with Trimmomatic ([@b27-mmr-16-04-4784]). High quality reads were mapped to the human genome (hg19, GRCh37 Genome Reference Consortium Human Reference 37) using modified BWA aligner 0.7.12 ([@b28-mmr-16-04-4784]) with BWA-MEM algorithm and default parameters to create SAM files. Picard 1.119 (<http://picard.sourceforge.net/>) was used to convert SAM files to compressed BAM files which were then sorted according to chromosome coordinates. The Genome Analysis Toolkit ([@b29-mmr-16-04-4784]) (GATK, version 3.4--0) was modified and used to locally realign the BAMs files at intervals with indel mismatches and recalibrate base quality scores of reads in BAM files ([@b30-mmr-16-04-4784]). Single nucleotide variants (SNVs) and short insertions/deletions (indels) were identified using VarScan2 2.3.9 ([@b31-mmr-16-04-4784]) with minimum variant allele frequency threshold set at 0.01 and P-value threshold for calling variants set at 0.05 to generate Variant Call Format (VCF) files. All SNVs/indels were annotated with ANNOVAR, and each SNV/indel was manually checked with the Integrative Genomics Viewer ([@b32-mmr-16-04-4784]) (IGV). Copy number variations (CNVs) were identified using ADTEx 1.0.4 ([@b33-mmr-16-04-4784]). The 416 gene exons sequencing report from Geneseeq Technology Inc also provided the drug treatment suggestions.

### Treatment protocol

From the 3rd generation, PDX tumors were permitted to grow to a volume of 150--200 mm^3^, then mice were randomized (6 mice with tumors per group and housed in per rearing cage) and dosing was administrated (AZD6244, 50 mg/kg p.o. qd; Capecitabine, 1.0 mM/kg p.o. qd) for 4 weeks. Mice were weighed for signs of toxicity and tumor size was evaluated once per week. TGI (Relative tumor growth inhibition) was calculated using the following formula: (1-T/C)%, where T means the relative tumor volume of the treated mice, and C means the relative tumor volume of the control mice.

### Immunohistochemistry

Specimen were fixed by 10 neutral formalin, then embedded in paraffin, sectioned (5 µm thick) and placed on slides for marker analysis. Sections were incubated with the primary antibodies overnight at 4°C, after blocking nonspecific antibody bindings. The streptavidin-biotin peroxidase complex method (Lab Vision, Nairobi, Kenya) was used for immunohistochemistry. The slides were photographed using an Olympus BX60 (Olympus, Hamburg, Germany).

### Statistical analysis

Results were presented as mean ± SD. Calculation and statistics were performed with Excel 2010 (Microsoft Corporation, Redmond, WA, USA) and GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). One-way ANOVA were used to analyze the significance of differences among groups. P\<0.05 was considered statistically significant.

Results
=======

### Patient characteristics and PDX model establishment

Pancreatic cancer bone metastasis (diagnosed as adenocarcinoma) tissues obtained at surgery from a 67-year-old female patient were subcutaneously implanted into BALB/c nude mice for the PDX model establishment. Tumors were re-implanted in new mice after reaching a volume of 1,000 mm^3^ as model passaging. The PDX model was serially passaged in animals 3 times. In order to further evaluate the PDX xenograft, immunohistochemical test was performed to identify if the patient\'s characteristics were retained in the PDX. Immunohistochemical expressions of CK19, CK7, and ki67 as well as the H&E staining showed that the pathological characteristics of the third passage xenograft was in accordance with the original patient sample ([Fig. 1](#f1-mmr-16-04-4784){ref-type="fig"}).

### Next generation sequencing for drug efficacy prediction

The sequencing of pancreatic cancer bone metastasis tissues of the patient tumor was conducted by Geneseeq Technology Inc. Totally, 13 pancreatic cancer-associated gene polymorphisms/mutations were found out of the 416 genes sequenced ([Tables I](#tI-mmr-16-04-4784){ref-type="table"} and [II](#tII-mmr-16-04-4784){ref-type="table"}). Based on the sequencing results and associated literatures, there were no under-clinical-trial targeted therapies of pancreatic cancer directly suitable for the genes detected. Therefore AZD6244 (AZD for short, also named as Selumetinib), a highly selective inhibitor against *MEK1*, was chosen as a potential therapy whose antitumor efficacy would then be evaluated in our PDX model.

### Efficacy evaluation of AZD6244 based on PDX model

To test whether the PDX model of pancreatic cancer bone metastasis was sensitive to the suggested therapy, antitumor-growth ability of AZD6244 were evaluated (Capecitabine for positive control). Since tumors volume reached 150--200 mm^3^, orally administration of AZD6244 (50 mg/kg), Capecitabine (1.0 mM/kg) or saline were then given once a day for 28 days. The mice were killed and excised tumors were measured. Then, relative tumor growth inhibition (TGI) was calculated as per the following formula: (1-T/C) %, where T is relative tumor volume of treated group mice, and C is relative tumor volume of control group mice. We found that single AZD6244 exhibited better efficacy (TGI, 33.03%) than Capecitabine (TGI, 26.93%), although without statistical significance. While the combination of both shown a significant synergistic effect, with TGI of 54.82% ([Fig. 2](#f2-mmr-16-04-4784){ref-type="fig"}). By western blotting, we evaluated the changes of ERK and p-ERK expressions in all groups, to find that p-ERK expressions were significantly suppressed in both single and combined AZD6244 groups ([Fig. 3](#f3-mmr-16-04-4784){ref-type="fig"}). By immunohistochemical staining, we found that PCNA (proliferating cell nuclear antigen) expressions in the AZD6244-treated groups were significantly suppressed, while caspase-3 (one of apoptosis associated antigens) expressions were significantly upregulated ([Figs. 4](#f4-mmr-16-04-4784){ref-type="fig"} and [5](#f5-mmr-16-04-4784){ref-type="fig"}). Therefore, AZD6244 was evaluated effective for the pancreatic cancer PDX model, thus might provide potential efficay in the clinical treatment of the very pancreatic cancer patient.

Disscussion
===========

Novel technologies contribute to the progress of the drug screening of pancreatic cancer during recent years. PDX models are being used for pancreatic cancer research in a series of studies ([@b2-mmr-16-04-4784],[@b7-mmr-16-04-4784],[@b34-mmr-16-04-4784],[@b35-mmr-16-04-4784]), while NGS technologies contribute to the translational research of pancreatic cancer ([@b36-mmr-16-04-4784]--[@b38-mmr-16-04-4784]). Multiple clinical studies have showed NGS and PDX will ameliorate personalized medicine and will be necessary for discovering novel therapeutic targets and biomarkers ([@b39-mmr-16-04-4784]). With the progress of these technologies, both are getting economically availble for patients. In our study, we combined PDX and NGS as an promising pattern of individualized drug screening to improve the clinical treatment of pancreatic cancer patients.

The PDX model of pancreatic cancer bone metastasis we established was comfirmed as highly molecularly stable with clinical patients in our study. Immunohistochemical expressions of CK19, CK7, and ki67 as well as the H&E staining showed that the pathological characteristics of the third passage xenograft was in accordance with the original patient tumor. Therefore, our PDX model could be considered as an 'Avatar' or a 'stand-in' of our pancreatic cancer patient, which would be a quite promising platform for drug screeing and evaluation.

In order to select the potential therapies customized for the pancreatic cancer patient, the bone metastasis tumor tissues were used for NGS detection (Geneseeq Technology Inc). However, based on the sequencing results and associated literatures, we found no under-clinical-trial targeted therapies of pancreatic cancer directly suitable for the genes detected. The sequencing report from Geneseeq Technology Inc also provided the alternative drug treatment suggestions, and MEK1 inhibitor was one of the most promising targeted therapies suggested. Then we concentrated on *MEK1*, a downstream gene *of KRAS*, which might be a potential target for treatment. Therefore we chose AZD6244, a MEK1 inhibitor, as a potential therapy which would then be evaluated in our PDX model.

In our study, we found that single AZD6244 exhibited better efficacy than Capecitabine, although without statistical significance. While the combination of both shown a significant synergistic effect, with TGI of 54.82%. AZD6244 significantly suppressed p-ERK expressions of the pancreatic cancer PDX model. AZD6244 significantly suppressed tumor cell proliferation and upregulated tumor cell apoptosis. Several studies have evaluated the effect of AZD6244 in pancreatic cancer in preclinical and clinical phase, and AZD6244 was shown to be effective in combination with EGFR/PIK3CA/STAT3 inhibitors in patients with pancreatic cancer ([@b40-mmr-16-04-4784]--[@b42-mmr-16-04-4784]). While we have shown that AZD6244 also has a synergistic effect in combination with Capecitabine. In addition, it was suggested that AZD6244 alone was mainly cytostatic, and apoptosis was mainly induced by combination therapies targeting multiple pathways ([@b43-mmr-16-04-4784]). While here in the present study, we shown that AZD6244 also suppressed tumor cell proliferation as a sinlge agent. Therefore, AZD6244 was evaluated as effective for the pancreatic cancer PDX model, thus might provide potential efficay in the clinical treatment of this pancreatic cancer patient.

In our study, AZD6244, a highly selective MEK1 inhibitor, was evaluated as effective for the pancreatic cancer PDX model, and thus might provide potential efficay in the clinical treatment of this pancreatic cancer patient. Although only one targeted agent was evaluated, we have successfully shown PDX-NGS based drug screening as a novel promising pattern of individualized drug screening to improve the clinical treatment of pancreatic cancer patients.
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![Immunohistochemical expressions compaired with PDX and patient tumor. The pathological characteristics of the third passage PDX xenograft was in accordance with the original patient sample. PDX, patient-derived xenograft; H&E, hematoxylin and eosin.](MMR-16-04-4784-g00){#f1-mmr-16-04-4784}

![(A) Antitumor-growth ability of AZD6244. (B) The single AZD6244 exhibited better efficacy than Capecitabine, while the combination of both shown a significant synergistic effect.](MMR-16-04-4784-g01){#f2-mmr-16-04-4784}

![Western blot analysis for changes of ERK and p-ERK expressions in all groups. The p-ERK expressions were significantly suppressed in both single and combined AZD6244 groups. \*\*P\<0.01, \*P\<0.05.](MMR-16-04-4784-g02){#f3-mmr-16-04-4784}

![Immunohistochemical staining shown that PCNA expressions in the AZD6244-treated groups were significantly suppressed.](MMR-16-04-4784-g03){#f4-mmr-16-04-4784}

![Immunohistochemical staining shown that caspase-3 expressions in the AZD6244-treated groups were significantly upregulated.](MMR-16-04-4784-g04){#f5-mmr-16-04-4784}

###### 

Next generation sequencing of the patient tumor.

  Gene     AA Change   Type       Allele call    Abundance
  -------- ----------- ---------- -------------- -----------
  BRCA2    N372H       SNP        Homozygous     
  BRIP1    R439X       SNP        Homozygous     48%
  CYP2D6   P34S        SNP        Homozygous     
  CYP3A5   CYP3A5\*3   SNP        Homozygous     
  EGFR     R521K       SNP        Homozygous     
  ERBB2    I655V       SNP        Homozygous     
  ERBB2    P1170A      SNP        Heterozygous   
  GSTM1                Deletion   Homozygous     
  GSTT1                Deletion   Homozygous     
  KRAS     G12D        SNP                       5%
  NQO1     P187S       SNP        Homozygous     
  PTEN     R173C       SNP                       37%
  UGT1A1   6/7TA       SNP        Heterozygous   

###### 

416 genes for analysis.

  ABCC2          DMNT3A    KDR        RAF1
  -------------- --------- ---------- ----------
  ACTB           DNM2      KIF1B      RARA
  ADH1B          DOCK1     KIT        RASGEF1A
  AIP            DOT1L     KMT2B      RB1
  AKT1           DPYD      KMT2C      RECQL4
  AKT2           DUSP2     KRAS       RELN
  AKT3           EBF1      LEF1       RET
  ALDH2          ECT2L     LMO1       RHBDF2
  ALK            EED       LSP1       RHOA
  AMER1          EGFR      LYN        RICTOR
  AP3B1          EGR1      LYST       RNF146
  APC            EP300     LZTR1      RNF43
  AR             EPCAM     MAP2K1     ROS1
  ARAF           EPHA3     MAP2K2     ROS1
  ARID1A         ERBB2     MAP2K4     RPTOR
  ARID2          ERBB3     MAP3K1     RRM1
  ARID5B         ERBB4     MCL1       RUNX1
  ASXL1          ERCC1     MDM2       SBDS
  ATM            ERCC2     MDM4       SDHA
  ATR            ERCC3     MECOM      SDHAF2
  ATRX           ERCC4     MED12      SDHB
  AURKA          ERCC5     MEF2B      SDHC
  AURKB          ESR1      MEN1       SDHD
  AXIN1          ETV1      MET        SERP2
  AXL            ETV4      MGMT       SETBP1
  B2M            EWSR1     MITF       SETD2
  BAP1           EXT1      MLH1       SF3B1
  BARD1          EXT2      MLL        SGK1
  BAT3           EZH2      MLLT10     SH2D1A
  BCL2           FANCA     MLPH       SLX4
  BCL2L1         FANCB     MPL        SMAD2
  BCL2L2         FANCC     MRE11A     SMAD3
  BCORL1         FANCD2    MSH2       SMAD4
  BIM(BCL2L11)   FANCE     MSH3       SMAD7
  BLM            FANCF     MSH6       SMARCA4
  BMPR1A         FANCG     MTHFR      SMARCB1
  BRAF           FANCI     MTOR       SMC1A
  BRCA1          FANCL     MUTYH      SMC3
  BRCA2          FANCM     MYC        SMO
  BRD4           FAT1      MYCL1      SOX2
  BRIP1          FBXO11    MYCN       SPOP
  BTG2           FCGR2B    MYD88      SRC
  BTK            FGF19     MYNN       SRSF2
  BTLA           FGFR1     NBN        STAG2
  BUB1B          FGFR2     NCSTN      STAT3
  c11orf30       FGFR3     NF1        STAT5A
  CALR           FGFR4     NF2        STAT5B
  CBL            FH        NFKBIA     STIL
  CCND1          FIP1L1    NKX2-1     STK11
  CCNE1          FLCN      NOTCH1     STMN1
  CCT6B          FLT1      NOTCH2     STX11
  CD22           FLT3      NPM1       STXBP2
  CD274          FLT4      NQO1       SUFU
  CD58           GADD45B   NRAS       SUZ12
  CD70           GATA1     NRG1       SYN3
  CDA            GATA2     NSD1       TCN2
  CDC73          GATA3     NT5C2      TEK
  CDH1           GATA4     NTRK1      TEKT4
  CDK10          GATA6     PAG1       TERC
  CDK12          GNA11     PAK3       TERT
  CDK4           GNA13     PALB2      TET2
  CDK6           GNAQ      PARK2      TGFBR2
  CDK8           GNAS      PAX5       TLE1
  CDKN1B         GPC3      PBRM1      TLE4
  CDKN1C         GRIN2A    PC         TMEM127
  CDKN2A         GRM3      PDCD1      TMPRSS2
  CDKN2B         GSTM1     PDCD1LG2   TNFAIP3
  CDKN2C         GSTP1     PDGFRA     TNFRSF14
  CEBPA          GSTT1     PDGFRB     TNFRSF17
  CEP57          HBA1      PDK1       TNFRSF19
  CHD4           HBA2      PHF6       TOP1
  CHEK1          HBB       PHOX2B     TOP2A
  CHEK2          HDAC1     PICK3R1    TP53
  CKS1B          HDAC2     PIK3C3     TP63
  CREBBP         HDAC4     PIK3CA     TPMT
  CRKL           HDAC7     PIK3CD     TRAF2
  CROT           HGF       PIK3R1     TRAF3
  CSF1R          HNF1A     PIK3R2     TRAF5
  CSF3R          HNF1B     PLCE1      TSC1
  CTCF           HRAS      PLK1       TSC2
  CTLA4          ID3       PMS1       TSHR
  CTNNB1         IDH1      PMS2       TTF1
  CUX1           IDH2      POLD1      TUBB3
  CXCR4          IGF1R     POLD3      TYMS
  CYLD           IGF2      POLE       TYR
  CYP2B6\*6      IKBKE     POT1       U2AF1
  CYP2B6\*6      IKZF1     PPP2R1A    UGT1A1
  CYP2C19\*2     IKZF2     PRDM1      UNC13D
  CYP2C9\*3      IKZF3     PRF1       VEGFA
  CYP2D6         IL13      PRKAR1A    VHL
  CYP2D6\*3      IL7R      PRKCI      WISP3
  CYP2D6\*4      INPP4B    PTCH1      WRN
  CYP2D6\*6      INPP5D    PTEN       WT1
  CYP3A4\*4      IRF1      PTPN11     XIAP
  CYP3A5\*3      IRF2      PTPN2      XPA
  DAB2           IRF4      PTPN6      XPC
  DAXX           IRF8      PTPRO      XPO1
  DDB2           JAK1      QKI        XRCC1
  DDR2           JAK2      RAC1       YAP1
  DDX1           JAK3      RAD21      ZAP70
  DHFR           JARID2    RAD50      ZBTB20
  DICER1         JUN       RAD51      ZNF217
  DIS3L2         KDM2B     RAD51C     ZNF703
  DLG2           KDM5A     RAD51D     ZRSR2
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